Increased IL‐10‐producing regulatory T cells are characteristic of severe cases of COVID‐19

The pandemic spread of the coronavirus SARS‐CoV‐2 is due, in part, to the immunological properties of the host–virus interaction. The clinical presentation varies from individual to individual, with asymptomatic carriers, mild‐to‐moderate‐presenting patients and severely affected patients. Variation in immune response to SARS‐CoV‐2 may underlie this clinical variation.

[1]  Hong-juan Liu,et al.  Frontline Science: COVID-19 infection induces readily detectable morphologic and inflammation-related phenotypic changes in peripheral blood monocytes , 2020, Journal of leukocyte biology.

[2]  Nicolas Carlier,et al.  Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients , 2020, Science.

[3]  Laura J. Simpson,et al.  A single-cell atlas of the peripheral immune response in patients with severe COVID-19 , 2020, Nature Medicine.

[4]  J. Greenbaum,et al.  Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.

[5]  G. Koh,et al.  Faculty Opinions recommendation of Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals , 2020, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[6]  Simon A. Jones,et al.  Outcomes Among HIV-Positive Patients Hospitalized With COVID-19 , 2020, Journal of acquired immune deficiency syndromes.

[7]  T. Hoffmann,et al.  Waste in covid-19 research , 2020, BMJ.

[8]  I. Amit,et al.  Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19 , 2020, Nature Medicine.

[9]  W. Liang,et al.  Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in China , 2020, Journal of Allergy and Clinical Immunology.

[10]  I. Amit,et al.  Host-Viral Infection Maps Reveal Signatures of Severe COVID-19 Patients , 2020, Cell.

[11]  A. Zangrillo,et al.  Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study , 2020, The Lancet Rheumatology.

[12]  M. Merad,et al.  Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages , 2020, Nature Reviews Immunology.

[13]  M. Metra,et al.  Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy , 2020, Autoimmunity Reviews.

[14]  M. Bickel,et al.  COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients , 2020, Infection.

[15]  R. Schwartz,et al.  Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 , 2020, Cell.

[16]  Xiaohu Zheng,et al.  Effective treatment of severe COVID-19 patients with tocilizumab , 2020, Proceedings of the National Academy of Sciences.

[17]  G. Gao,et al.  Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19 , 2020, Journal of Allergy and Clinical Immunology.

[18]  J. O’Grady,et al.  Co-infections: potentially lethal and unexplored in COVID-19 , 2020, The Lancet Microbe.

[19]  F. Rieux-Laucat,et al.  Impaired type I interferon activity and exacerbated inflammatory responses in severe Covid-19 patients , 2020, medRxiv.

[20]  Aaron J. Wilk,et al.  A single-cell atlas of the peripheral immune response to severe COVID-19 , 2020, medRxiv.

[21]  V. Lougaris,et al.  A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia , 2020, Journal of Allergy and Clinical Immunology.

[22]  M. Girardis,et al.  Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia , 2020, Nature Communications.

[23]  M. Chiarini,et al.  Two X‐linked agammaglobulinemia patients develop pneumonia as COVID‐19 manifestation but recover , 2020, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[24]  Felipe García,et al.  COVID-19 in patients with HIV: clinical case series , 2020, The Lancet HIV.

[25]  E. Coomes,et al.  Interleukin‐6 in Covid‐19: A systematic review and meta‐analysis , 2020, medRxiv.

[26]  Yuzhang Wu,et al.  The Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Directly Decimates Human Spleens and Lymph Nodes , 2020, medRxiv.

[27]  Taojiao Wang,et al.  Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. , 2020, The Journal of clinical investigation.

[28]  Baojun Zhang,et al.  Analysis of adaptive immune cell populations and phenotypes in the patients infected by SARS-CoV-2 , 2020, medRxiv.

[29]  Z. Tian,et al.  Functional exhaustion of antiviral lymphocytes in COVID-19 patients , 2020, Cellular & Molecular Immunology.

[30]  Yong-tang Zheng,et al.  Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients , 2020, Cellular & Molecular Immunology.

[31]  Xiaohu Zheng,et al.  Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients , 2020, National science review.

[32]  C. Roca,et al.  AutoSpill: a method for calculating spillover coefficients in high-parameter flow cytometry , 2020 .

[33]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[34]  Yuhui Yang,et al.  The Potential Role of IL-6 in Monitoring Coronavirus Disease 2019 , 2020 .

[35]  W. Ye,et al.  Study of the lymphocyte change between COVID-19 and non-COVID-19 pneumonia cases suggesting other factors besides uncontrolled inflammation contributed to multi-organ injury , 2020, medRxiv.

[36]  Bo Diao,et al.  Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19) , 2020, Frontiers in Immunology.

[37]  Chuan Qin,et al.  Dysregulation of immune response in patients with COVID-19 in Wuhan, China , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[38]  R. Webby,et al.  Severe Influenza Is Characterized by Prolonged Immune Activation: Results From the SHIVERS Cohort Study , 2018, The Journal of infectious diseases.

[39]  H. Bouabe,et al.  Influenza A virus-induced release of interleukin-10 inhibits the anti-microbial activities of invariant natural killer T cells during invasive pneumococcal superinfection , 2016, Mucosal Immunology.

[40]  V. Martín,et al.  IL-10: A Multifunctional Cytokine in Viral Infections , 2017, Journal of immunology research.

[41]  C. Weaver,et al.  Br Ief Definitive Repor T , 2022 .

[42]  B. Stockinger,et al.  Tc17 cells are a proinflammatory, plastic lineage of pathogenic CD8+ T cells that induce GVHD without antileukemic effects. , 2015, Blood.

[43]  T. Donner,et al.  Interleukin-10 paradox: A potent immunoregulatory cytokine that has been difficult to harness for immunotherapy. , 2015, Cytokine.

[44]  Christine E. Becker,et al.  Influenza virus-induced lung injury: pathogenesis and implications for treatment , 2015, European Respiratory Journal.

[45]  F. Baron,et al.  Immune Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Following Flu-TBI versus TLI-ATG Conditioning , 2015, Clinical Cancer Research.

[46]  E. Wherry,et al.  Viral Antigen Induces Differentiation of Foxp3+ Natural Regulatory T Cells in Influenza Virus–Infected Mice , 2013, The Journal of Immunology.

[47]  J. Kolls,et al.  T cell-mediated host immune defenses in the lung. , 2013, Annual review of immunology.

[48]  A. Rudensky,et al.  Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. , 2011, Immunity.

[49]  F. Sallusto,et al.  Dissecting the human immunologic memory for pathogens , 2011, Immunological reviews.

[50]  D. Metzger,et al.  A Detrimental Effect of Interleukin-10 on Protective Pulmonary Humoral Immunity during Primary Influenza A Virus Infection , 2010, Journal of Virology.

[51]  Steven L. Kunkel,et al.  Negative regulation of MyD88-dependent signaling by IL-10 in dendritic cells , 2009, Proceedings of the National Academy of Sciences.

[52]  T. Nomura,et al.  Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. , 2009, Immunity.

[53]  H. Ochs,et al.  IL-10 Deficiency Unleashes an Influenza-Specific Th17 Response and Enhances Survival against High-Dose Challenge1 , 2009, The Journal of Immunology.

[54]  Anthony S Fauci,et al.  Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. , 2008, The Journal of infectious diseases.

[55]  E. Chi,et al.  Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. , 2008, Immunity.

[56]  Jiang Gu,et al.  Pathology and Pathogenesis of Severe Acute Respiratory Syndrome , 2007, The American Journal of Pathology.

[57]  T. van der Poll,et al.  IL-10 Is an Important Mediator of the Enhanced Susceptibility to Pneumococcal Pneumonia after Influenza Infection , 2004, The Journal of Immunology.

[58]  E. Fikrig,et al.  Inhibition of Th1 differentiation by IL-6 is mediated by SOCS1. , 2000, Immunity.